Eris Lifesciences joins hands with Medtronic for diabetes monitoring initiative

04 Jan 2019 Evaluate

Eris Lifesciences and India Medtronic, a wholly owned subsidiary of Medtronic plc, the global leader in medical technology, have collaborated for a diabetes monitoring initiative in India. The two companies will utilize their respective strengths in helping patients monitor their diabetes better.

Medtronic will bring to India its latest US Food and Drug Administration (USFDA) approved Guardian Connect device for real-time evaluation of glucose variability in diabetes patients. Eris through its national reach will provide the device at clinics and healthcare delivery units under its patient care initiative. Guardian Connect is the world's first Smart Continuous Glucose Monitoring System connected with smartphone displays for real-time data viewing of glucose levels, without a separate hardware monitor.

Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.

Eris Lifesciences Share Price

915.60 2.65 (0.29%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.